SRR934870
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 80.71616294349539
- age_years
- 33
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.504
- MYC_TARGETS_V1+0.463
- NOTCH_SIGNALING+0.437
- MITOTIC_SPINDLE+0.410
- WNT_BETA_CATENIN_SIGNALING+0.402
- G2M_CHECKPOINT+0.398
- PROTEIN_SECRETION+0.290
- UV_RESPONSE_DN+0.281
- HEDGEHOG_SIGNALING+0.271
- DNA_REPAIR+0.252
Top 10 suppressed
- KRAS_SIGNALING_DN-0.366
- ANGIOGENESIS-0.270
- MYOGENESIS-0.265
- PANCREAS_BETA_CELLS-0.227
- COAGULATION-0.202
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.194
- SPERMATOGENESIS-0.194
- HYPOXIA-0.185
- TNFA_SIGNALING_VIA_NFKB-0.114
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934799 | — | — | 0.926 |
| 2 | 1F4B7E2E-E242-410A-AE78-8FC412D3C0A9 | — | — | 0.924 |
| 3 | 63204446-7AA0-40DC-996D-440F4E19AD0F | — | — | 0.911 |
| 4 | B7B9B5C1-C11D-47B8-B2F8-A5660AB961C1 | — | — | 0.910 |
| 5 | 9198B2FA-637D-44B2-B6E8-24B5681737AA | — | — | 0.909 |
| 6 | 24F914FE-3DF0-4286-9231-9D525A777306 | — | — | 0.909 |
| 7 | SRR934727 | — | — | 0.904 |
| 8 | D5E8379B-621C-4551-9B13-E63B1B068488 | — | — | 0.899 |
| 9 | F35F85A8-B3CD-4116-990F-94B2E432F902 | — | — | 0.899 |
| 10 | SRR934777 | — | — | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.504 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.463 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.437 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.402 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.398 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.281 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.271 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.252 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.244 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.242 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.238 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.235 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.231 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.115 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.104 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.099 | Inavolisib | — uncovered |
| PEROXISOME | 0.093 | Idelalisib | — uncovered |